[September 22, 2014]

Research and Markets: Sustained Release Ocular Drug Delivery Systems 2014-2019

Research and Markets (http://www.researchandmarkets.com/research/zw5wkb/sustained_release) has announced the addition of the "Sustained Release Ocular Drug Delivery Systems" report to their offering.

The report covers various aspects such as technological progress, product pipeline, industry and academic research programs to assess new evolving opportunities.

One of the key objectives of this report is to understand the current and future state of the ophthalmic sustained drug delivery market.

This is done by analysing the following:

• Ophthalmic sustained release drug delivery systems currently available in the market
• Ophthalmic sustained release drug delivery systems currently in the pipeline
• Leading technology providers and drug delivery systems developers
• Most commonly targeted indications and drugs being delivered
• Size of target consumer segments

The base year for the report is 2013. The report provides market forecasts for th following two time horizons: 2014 - 2019 and 2019 - 2024, respectively. We have discussed, in detail, key drivers behind the likely growth of ophthalmic drug delivery systems market. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery system products based on the current expected launch timelines, adoption rates and the estimated end-use price points. The figures mentioned in this report are in USD, unless otherwise specified.

Executive Summary:

• Vitrasert, launched in 1996, was the first ocular implant. It was, however, taken off the market in 2013. Only three more implants have received regulatory approval since 1996; these are Retisert, Ozurdex and Iluvien.
• Out of 42 sustained release ocular drug delivery systems (marketed / under development), 3 are already marketed for specific indications and 14 are in Phase II or Phase III of development.
• Diabetic Macular Edema (DME) will provide the much needed boost to the sustained release ocular drug delivery systems market in the short-term. The potential in the market is huge with a high target population, which is growing significantly due to the rise in cases of diabetes.
• In the mid to long term, the growth will be boosted by launch of sustained release systems for glaucoma and AMD (News - Alert). At least three companies have sustained release systems delivering prostaglandin analogues in phase II development and one in phase I/II for the treatment of glaucoma and ocular hypertension.
• The overall market is likely to be more than USD 1 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Product Profiles And Sales Forecast

6. Company Profiles

7. SWOT Analysis

8. Interview Transcripts

9. Conclusion

10. Appendix 1: Tabulated Data

11. Appendix 2: List of Companies and Organizations

For more information visit http://www.researchandmarkets.com/research/zw5wkb/sustained_release

[ Back To TMCnet.com's Homepage ]